Oncogenic fusion protein BCR-FGFR1 requires the breakpoint cluster region-mediated oligomerization and chaperonin Hsp90 for activation. [PDF]
, 2020 Mutation and translocation of fibroblast growth factor receptors often lead to aberrant signaling and cancer. This work focuses on the t(8;22)(p11;q11) chromosomal translocation which creates the breakpoint cluster region (BCR) fibroblast growth factor ...
Bisom-Rapp, Ezra W +4 more
core +2 more sources
Haematologica, 2017 High mobility group AT-hook 2 (HMGA2) is an architectural transcription factor that is negatively regulated by let-7 microRNA through binding to it’s 3′-untranslated region. Transgenic mice expressing Hmga2 with a truncation of its 3′-untranslated region
Chih-Cheng Chen +11 more
doaj +1 more source
Arterial and Venous Thrombosis in Patients with Myeloproliferative Neoplasms
Jurnal Penyakit Dalam Indonesia, 2019 Introduction. Myeloproliferative neoplasm (MPN) is a hematologic disorder that consists of polycythemia vera (PV), essential thrombocythemia (ET and primary myelofibrosis (PMF) and complication of thrombosis is frequently found in patients with MPN. This
Lugyanti Sukrisman
doaj +1 more source
Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder [PDF]
, 2015 Although more than 90% systemic mastocytosis (SM) patients express gain of function mutations in the KIT receptor, recent next generation sequencing has revealed the presence of several additional genetic and epigenetic mutations in a subset of these ...
Chatterjee, Anindya +2 more
core +2 more sources
Clinical Case Reports, 2023 Key Clinical Message No formal treatment guidelines for MDS/MPN‐RS‐T exist. With salient features such as anemia and thrombocytosis, management is individualized and aims to address anemia, thrombosis, and in some cases acquired von Willebrand's disease.
Hannah Cherniawsky, Habib Moshref Razavi
doaj +1 more source
The paradox of cancer genes in non-malignant conditions: implications for precision medicine. [PDF]
, 2020 Next-generation sequencing has enabled patient selection for targeted drugs, some of which have shown remarkable efficacy in cancers that have the cognate molecular signatures.
Adashek, Jacob J +3 more
core
Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms [PDF]
, 2015 Myeloproliferative neoplasms (MPN) are a diverse group of chronic hematological disorders that involve unregulated clonal proliferation of white blood cells.
Kapur, Reuben, Pandey, Ruchi
core +1 more source
Cerebral salt wasting in a patient with myeloproliferative neoplasm
BMC Neurology, 2019 Background Cerebral salt wasting (CSW) is a rare metabolic disorder with severe hyponatremia and volume depletion usually caused by brain injury like trauma, cerebral lesion, tumor or a cerebral hematoma.
Lea Orlik +3 more
doaj +1 more source
Implementation of the JAK2V617F mutation analysis in the pathway of suspected myeloproliferative neoplasms in Groote Schuur Hospital [PDF]
, 2016 We studied the implementation of JAK2 mutation analysis in conjunction with the World Health Organisation (WHO) guidelines in the pathway to MPN diagnosis in 279 patients presenting with one of three clinical scenarios: erythrocytosis, OR leukocytosis ...
Poulet, Erma
core
The Calreticulin gene and myeloproliferative neoplasms [PDF]
, 2016 The Philadelphia negative myeloproliferative neoplasms include polycythaemia vera (PV), essential thrombocytopenia (ET) and primary myelofibrosis (PMF).
Clinton, Aoibhinn +1 more
core +1 more source